Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction.
The development of suitable experimental systems for studying HIV latency in primary cells that permit detailed biochemical analyses and the screening of drugs is a critical step in the effort to develop viral eradication strategies. Primary CD4(+) T cells were isolated from peripheral blood and amplified by antibodies to the T-cell receptor (TCR). The cells were then infected by lentiviral vectors carrying fluorescent reporters and either the wild-type Tat gene or the attenuated H13L Tat gene. After sorting for the positive cells and reamplification, the infected cells were allowed to spontaneously enter latency by long-term cultivation on the H80 feeder cell line in the absence of TCR stimulation. By 6 weeks almost all of the cells lost fluorescent protein marker expression; however, more than 95% of these latently infected cells could be reactivated after stimulation of the TCR by alpha-CD3/CD28 antibodies. Chromatin immunoprecipitation assays showed that, analogously to Jurkat T cells, latent proviruses in primary CD4(+) T cells are enriched in heterochromatic markers, including high levels of CBF-1, histone deacetylases, and methylated histones. Upon TCR activation, there was recruitment of NF-kappaB to the promoter and conversion of heterochromatin structures present on the latent provirus to active euchromatin structures containing acetylated histones. Surprisingly, latently infected primary cells cannot be induced by tumor necrosis factor alpha because of a restriction in P-TEFb levels, which can be overcome by activation of the TCR. Thus, a combination of restrictive chromatin structures at the HIV long terminal repeat and limiting P-TEFb levels contribute to transcriptional silencing leading to latency in primary CD4(+) T cells.
Tyagi
Mudit
M
Department of Molecular Biology and Microbiology, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106-4960, USA.
Pearson
Richard John
RJ
Karn
Jonathan
J
D015496:CD4-Positive T-Lymphocytes / Q000821:virology*; D002478:Cells, Cultured; D022041:Euchromatin / Q000737:chemistry / Q000378:metabolism; D015967:Gene Expression Regulation, Viral; D020868:Gene Silencing; D006678:HIV / Q000502:physiology*; D006570:Heterochromatin / Q000737:chemistry / Q000378:metabolism; D006655:Histone Deacetylases / Q000032:analysis; D006657:Histones / Q000032:analysis; D054884:Host-Pathogen Interactions; D006801:Humans; D047468:Immunoprecipitation; D016328:NF-kappa B / Q000378:metabolism; D042925:Positive Transcriptional Elongation Factor B / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D011485:Protein Binding; D011948:Receptors, Antigen, T-Cell / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D017735:Virus Latency
D022041:Euchromatin; D006570:Heterochromatin; D006657:Histones; D016328:NF-kappa B; D011948:Receptors, Antigen, T-Cell; D014409:Tumor Necrosis Factor-alpha; D042925:Positive Transcriptional Elongation Factor B; D006655:Histone Deacetylases
J Immunol. 1994 Aug 1;153(3):952-9
7913116
EMBO J. 2007 Jan 24;26(2):412-23
17245431
Nature. 1995 Jan 12;373(6510):123-6
7816094
Nature. 1999 Oct 14;401(6754):708-12
10537110
Retrovirology. 2007 Jul 11;4:47
17625008
Mol Cell. 2009 Jun 26;34(6):696-709
19560422
Annu Rev Immunol. 2000;18:665-708
10837072
J Immunol. 1991 Apr 15;146(8):2488-94
1707907
AIDS. 2004 May 21;18(8):1101-8
15166525
J Virol. 1998 Dec;72(12):9881-8
9811724
J Virol. 2009 Apr;83(7):3078-93
19144703
Trends Mol Med. 2004 Nov;10(11):525-31
15519278
J Virol. 2002 Dec;76(24):13077-82
12438635
J Virol. 2005 Nov;79(22):14179-88
16254353
J Virol. 2002 Sep;76(17):8776-86
12163598
PLoS Pathog. 2009 Jun;5(6):e1000495
19557157
Cell Host Microbe. 2008 Aug 14;4(2):123-33
18692772
J Virol. 2004 Jun;78(12):6122-33
15163705
EMBO J. 2003 Apr 15;22(8):1868-77
12682019
PLoS Pathog. 2007 Oct 12;3(10):1459-69
17937499
J Exp Med. 2001 Dec 17;194(12):1731-41
11748275
Nat Med. 2007 Oct;13(10):1241-7
17906637
J Immunol. 2008 Dec 1;181(11):7713-20
19017960
Nat Med. 2001 Apr;7(4):459-64
11283673
J Virol. 2007 Jul;81(14):7424-34
17475639
Nat Med. 2000 Jan;6(1):82-5
10613829
J Virol. 2000 Aug;74(15):6790-9
10888618
JAMA. 1999 Nov 3;282(17):1627-32
10553788
Int Immunol. 2008 Sep;20(9):1189-99
18635582
Nature. 1995 Jan 12;373(6510):117-22
7529365
Nature. 1987 Apr 16-22;326(6114):711-3
3031512
J Virol. 2004 Feb;78(3):1160-8
14722271
J Virol. 2003 Aug;77(15):8602-6
12857933
Nat Med. 1999 May;5(5):512-7
10229227
EMBO J. 1993 Aug;12(8):3249-59
8344262
Immunity. 1997 Mar;6(3):235-44
9075924
Nature. 1999 Oct 28;401(6756):874-5
10553903
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9403-8
19470482
EMBO J. 1996 Mar 1;15(5):1112-20
8605881
EMBO J. 2007 Dec 12;26(24):4985-95
18007589
EMBO J. 2006 Aug 9;25(15):3596-604
16874302
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12955-60
14569007
J Clin Invest. 2009 Nov;119(11):3473-86
19805909
EMBO J. 2007 Jan 24;26(2):424-35
17245432
Virology. 2009 Apr 25;387(1):98-108
19268337
PLoS Pathog. 2006 Jul;2(7):e68
16839202
J Virol. 2005 Jun;79(11):6610-9
15890899
Microbiol Mol Biol Rev. 2006 Sep;70(3):646-59
16959964
Nat Immunol. 2000 Nov;1(5):433-40
11062504
J Virol. 2003 Apr;77(7):4025-32
12634362
J Virol. 1998 Feb;72(2):1666-70
9445075
Cell Host Microbe. 2008 Aug 14;4(2):134-46
18692773
J Infect Dis. 2008 Mar 1;197(5):714-20
18260759
J Exp Med. 1997 Nov 3;186(9):1407-18
9348298
Virology. 2006 Nov 25;355(2):127-37
16919704
J Virol. 2008 Dec;82(24):12291-303
18829756